Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy
Warm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60–80% response rate. Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate. We report a case of sev...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/9181698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556696426250240 |
|---|---|
| author | Kim Ma Stephen Caplan |
| author_facet | Kim Ma Stephen Caplan |
| author_sort | Kim Ma |
| collection | DOAJ |
| description | Warm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60–80% response rate. Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate. We report a case of severe wAIHA secondary to Waldenström macroglobulinemia with life threatening intravascular hemolysis refractory to prednisone, rituximab, splenectomy, and plasmapheresis. A four-week treatment of eculizumab in this heavily pretreated patient resulted in a sustained increase in hemoglobin and transfusion independence, suggesting a role for complement inhibition in refractory wAIHA. |
| format | Article |
| id | doaj-art-9e35432878b14dd8ba55da0b2f076f5a |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-9e35432878b14dd8ba55da0b2f076f5a2025-02-03T05:44:42ZengWileyCase Reports in Hematology2090-65602090-65792016-01-01201610.1155/2016/91816989181698Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement TherapyKim Ma0Stephen Caplan1Department of Medicine, Division of Hematology, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Room E-725, Montreal, QC, H3T 1E2, CanadaDepartment of Medicine, Division of Hematology, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Room E-725, Montreal, QC, H3T 1E2, CanadaWarm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60–80% response rate. Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate. We report a case of severe wAIHA secondary to Waldenström macroglobulinemia with life threatening intravascular hemolysis refractory to prednisone, rituximab, splenectomy, and plasmapheresis. A four-week treatment of eculizumab in this heavily pretreated patient resulted in a sustained increase in hemoglobin and transfusion independence, suggesting a role for complement inhibition in refractory wAIHA.http://dx.doi.org/10.1155/2016/9181698 |
| spellingShingle | Kim Ma Stephen Caplan Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy Case Reports in Hematology |
| title | Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy |
| title_full | Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy |
| title_fullStr | Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy |
| title_full_unstemmed | Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy |
| title_short | Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy |
| title_sort | refractory igg warm autoimmune hemolytic anemia treated with eculizumab a novel application of anticomplement therapy |
| url | http://dx.doi.org/10.1155/2016/9181698 |
| work_keys_str_mv | AT kimma refractoryiggwarmautoimmunehemolyticanemiatreatedwitheculizumabanovelapplicationofanticomplementtherapy AT stephencaplan refractoryiggwarmautoimmunehemolyticanemiatreatedwitheculizumabanovelapplicationofanticomplementtherapy |